Glaukos (NYSE:GKOS) Director Leana Wen Sells 525 Shares

Glaukos Corporation (NYSE:GKOS) Director Leana Wen sold 525 shares of the firm’s stock in a transaction on Friday, July 31st. The shares were sold at an average price of $167.63, for a total value of $88,005.75. Following the transaction, the director directly owned 21,092 shares of the company’s stock, valued at $3,535,651.96. This represents a 2.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Glaukos Trading Up 2.5%

NYSE:GKOS opened at $170.90 on Tuesday. The company’s 50-day simple moving average is $139.11 and its 200 day simple moving average is $125.60. Glaukos Corporation has a one year low of $73.16 and a one year high of $184.00. The firm has a market capitalization of $10.08 billion, a P/E ratio of -52.59 and a beta of 0.75. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.07. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The company had revenue of $185.61 million for the quarter, compared to the consensus estimate of $150.93 million. During the same quarter in the prior year, the business posted ($0.24) EPS. The firm’s quarterly revenue was up 49.6% compared to the same quarter last year. As a group, analysts forecast that Glaukos Corporation will post -0.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Glaukos

Several large investors have recently added to or reduced their stakes in GKOS. Summit Global Investments purchased a new stake in shares of Glaukos in the second quarter worth $580,000. Oppenheimer Asset Management Inc. purchased a new position in shares of Glaukos during the 2nd quarter valued at $2,734,000. Walleye Capital LLC bought a new position in Glaukos in the 2nd quarter worth $3,750,000. Handelsbanken Fonder AB boosted its holdings in Glaukos by 5.9% in the 2nd quarter. Handelsbanken Fonder AB now owns 19,800 shares of the medical instruments supplier’s stock worth $2,767,000 after buying an additional 1,100 shares during the period. Finally, Valeo Financial Advisors LLC increased its stake in Glaukos by 4.7% in the 2nd quarter. Valeo Financial Advisors LLC now owns 9,892 shares of the medical instruments supplier’s stock worth $1,383,000 after buying an additional 440 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on GKOS shares. Citigroup increased their price objective on Glaukos from $175.00 to $188.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a report on Friday, July 17th. HC Wainwright boosted their price target on Glaukos from $168.00 to $195.00 and gave the company a “buy” rating in a research note on Thursday. Stifel Nicolaus upped their price target on shares of Glaukos from $175.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday. Finally, BTIG Research increased their price objective on shares of Glaukos from $164.00 to $193.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Twelve research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $177.33.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.